Evidence map›Paper›PMID 35778691›Full record

ArticleBMC cancer2022

A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma.

Matthew C Hynes, Paul Nguyen, Patti A Groome, Yuka Asai, Meaghan E Mavor, Tara D Baetz, Timothy P Hanna

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Matthew C HynesSchool of Medicine, Queen's University, Kingston, ON, Canada.
Paul NguyenICES Queen's, Queen's University, Kingston, ON, Canada.
Patti A GroomeDivision of Cancer Care and Epidemiology, Department of Public Health Sciences, Queen's Cancer Research Institute, Queen's University, 10 Stuart Street, 2nd Level, Kingston, ON, K7L 3N6, Canada.
Yuka AsaiSchool of Medicine, Queen's University, Kingston, ON, Canada.
Meaghan E MavorDivision of Cancer Care and Epidemiology, Department of Public Health Sciences, Queen's Cancer Research Institute, Queen's University, 10 Stuart Street, 2nd Level, Kingston, ON, K7L 3N6, Canada.
Tara D BaetzSchool of Medicine, Queen's University, Kingston, ON, Canada.
Timothy P HannaSchool of Medicine, Queen's University, Kingston, ON, Canada. Tim.Hanna@KingstonHSC.ca.

Funding

CIHR MOP 137022Ontario Institute for Cancer Research #IA-035
6 · The paper itself

Abstract

backgroundThe 8

methodsThis retrospective cohort-study included 6,414 patients from the population-based Ontario Cancer Registry diagnosed with cutaneous melanoma between January 1, 2007 and December 31, 2012. Kaplan-Meier curves estimated the melanoma-specific survival (MSS) and overall survival (OS). Cox proportional hazard models were used to estimate adjusted hazard ratios for MSS and OS across stage groups. The Schemper-Henderson measure was used to assess the variance explained in the Cox regression.

resultsIn our sample, 21.3% of patients were reclassified with TNM8 from TNM7; reclassifications in stage II were uncommon, and 44.1% of patients in stage III were reclassified to a higher subgroup. Minimal changes in MSS curves were observed between editions, but the stage IIB curve decreased and the stage IIIC curve increased. For TNM8, Stage I (n = 4,556), II (n = 1,206), III (n = 598), and IV (n = 54) had an estimated 5-year MSS of 98.4%, 82.5%, 66.4%, and 14.4%, respectively. Within stage III, IIIA 5-year MSS was 91.7% while stage IIID was 23.5%. HRs indicated that TNM8 more evenly separates subgroups once adjusted for patient- and disease-characteristics. The variance in MSS explained by TNM7 and TNM8 is 18.9% and 19.7%, respectively.

conclusionTNM8 performed well in our sample, with more even separation of stage subgroups and a modest improvement in predictive ability compared to TNM7.

Indexed as

MelanomaSkin NeoplasmsCutaneous Malignant MelanomaHumansNeoplasm StagingRetrospective StudiesCohort studiesMelanomaNeoplasm stagingOntarioPrognosisSkin neoplasmsSurvival analysis

Identifiers

PMID35778691
PMCPMC9248086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.